Ridding Cancer Patients Of “Undruggable Targets” Could Be A Boon For This Biotech Stock

What makes the biotech stock featured in today’s article a buy according to an analyst who recently initiated coverage of it? The potential for its treatments to rid patients of troublesome proteins – including those that are known to drive cancer – that have proven to be “undruggable” with existing technologies. For the biotech in question, and more on its potential protein degradation treatments for prostate and breast cancers, CLICK HERE.